1.A Case of Abdominal Aortic Aneurysm Involved by Acute Type B Dissection Treated with One-Stage OPCAB and Y-Graft Replacement
Yoshimori Araki ; Michio Sasaki ; Toshiaki Akita ; Akihiko Usui ; Kazuo Nishimoto ; Masayoshi Kobayashi ; Kimihiro Komori ; Yuichi Ueda
Japanese Journal of Cardiovascular Surgery 2005;34(1):55-58
An 83-year-old man had acute type B aortic dissection combined with a large athelosclerotic abdominal aortic aneurysm (AAA) over 8cm in diameter. The dissection advanced into the wall of the AAA. The patient was treated with strict medical therapy for two months and successfully underwent an early elective abdominal aortic repair concomitant with off-pump aortocoronary bypass grafting. This strategy of meticulous medical management may improve clinical outcome for the acute phase in such rare cases.
2.Gingyo Gedokusan vs Oseltamivir for the Treatment of Uncomplicated Influenza and Influenza-like illness : An Open-label Prospective Study
Kentaro Iwata ; Wataru Igarashi ; Midori Honjo ; Takashi Nishimoto ; Kyoko Shinya ; Akiko Makino ; Kazuo Mitani ; Yoshiko Tatsumi ; Hiroyuki Ninomiya ; Kumi Higasa ; Seiichiro Usuki ; Hiroki Kagawa ; Daisuke Uchida ; Kohei Takimoto ; Rei Suganaga ; Hiroo Matsuo ; Yuichiro Oba ; Mami Horigome ; Hideaki Oka ; Goh Ohji ; Yasuhisa Abe ; Hiroyuki Yoshida ; Shohiro Kinoshita ; Midori Hirai
General Medicine 2013;14(1):13-22
Background: Gingyo-gedoku-san (GGGS) is an herbal medicine approved for upper respiratory infections in Japan. We conducted an open-label, multi-center, prospective trial, comparing GGGS with oseltamivir in patients with influenza and influenza-like illness (ILI) as a pilot study.
Methods: Subjects were healthy persons aged between 16 and 40, and were enrolled from January 12, 2010 to March 24, 2011. Fifteen patients were enrolled in this trial (8 and 7 for GGGS and oseltamivir, respectively). RT-PCR was positive for pandemic influenza A (H1N1) in 10 patients. The patients were provided with either GGGS or oseltamivir for 5 days. The primary outcome was mortality and/or hospitalization 7 days after the initial diagnosis. Body temperature and other clinical characteristics were also evaluated.
Results: All patients recovered from illness without complication or hospitalization. The mean time to resolve symptoms for the GGGS and oseltamivir groups was 3.9 days and 3.3 days, respectively (p=0.43). The GGGS group appeared to have a smaller symptom score AUC than the oseltamivir group, (p=0.26). Time to recover activity level appeared to be shorter in the GGGS group (p=0.10), with shorter time to recover health status (p=0.02). Sub-group analysis on patients with positive PCR showed similar results between the two groups.
Conclusion: GGGS was associated with symptom improvements resembling oseltamivir for both influenza and ILI. Randomized controlled trials involving larger sample sizes are needed to confirm these results.